^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD20 inhibitor

    Related drugs:
    13h
    The SREBF2-ACOT7 axis promotes tumor progression and predicts prognosis in diffuse large b-cell lymphoma. (PubMed, Sci Rep)
    Although the R-CHOP regimen effectively cures 60-70% of patients, 30-40% of patients relapse or develop resistance, highlighting the need for new biomarkers to improve prognosis and therapeutic strategies...Our findings suggest that the SREBF2-ACOT7 axis plays a critical role in DLBCL by promoting tumor cell growth, invasion, and survival. ACOT7 could serve as a potential prognostic biomarker and therapeutic target for DLBCL, providing new insights into the molecular mechanisms of this aggressive lymphoma.
    Journal
    |
    SREBF2 (Sterol Regulatory Element Binding Transcription Factor 2)
    |
    Rituxan (rituximab)
    22h
    Effects of Ocrevus in Relapsing Multiple Sclerosis (clinicaltrials.gov)
    P4, N=60, Active, not recruiting, Georgia State University | Trial completion date: Sep 2025 --> Dec 2025
    Trial completion date
    |
    Ocrevus (ocrelizumab)
    1d
    Extensive multifocal extranodal diffuse large B-cell lymphoma involving parotid, breast, gastrointestinal tract, and dorsal spine: a case report. (PubMed, Ann Med Surg (Lond))
    The patient was given R-CHOP chemotherapy and intrathecal methotrexate with a favorable early response...Image-guided biopsy and immunophenotyping at an early stage are crucial to avoid misdiagnosis and guide appropriate therapy. Individualized and risk-adapted approaches are crucial in maximizing the outcome in such aggressive and rare presentations.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • BCL6 (B-cell CLL/lymphoma 6)
    |
    CD20 positive
    |
    Rituxan (rituximab)
    1d
    Assessing Peripheral Blood Biomarkers and Predictive Patterns in Multiple Sclerosis Using Cytokines and Immune Gene Expression Profiles in Ocrelizumab-Treated Patients: Tracking Tumor Necrosis Factor. (PubMed, Int J Mol Sci)
    This result implies that PBMCs' TNF mRNA expression might be potentially considered as a prognostic biomarker of ocrelizumab effectiveness in MS patients. However, further studies comprising large cohorts and additional immunological parameters are warranted.
    Journal • Gene Expression Profile
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CD86 (CD86 Molecule)
    |
    Ocrevus (ocrelizumab)
    2d
    Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular Lymphoma (clinicaltrials.gov)
    P2, N=29, Suspended, City of Hope Medical Center | Recruiting --> Suspended
    Trial suspension
    |
    lenalidomide • Epkinly (epcoritamab-bysp)
    3d
    Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease (clinicaltrials.gov)
    P2, N=25, Recruiting, Ruijin Hospital
    New P2 trial
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Rituxan (rituximab) • Inokai (orelabrutinib) • lisaftoclax (APG-2575)
    3d
    BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. (PubMed, J Clin Oncol)
    Pirtobrutinib demonstrated superiority over BendaR in IRC-assessed PFS in treatment-naïve CLL/SLL. OS trends favored pirtobrutinib despite the study design allowing for crossover. Pirtobrutinib was well tolerated, consistent with its known safety profile, and more favorable than BendaR.
    P3 data • Journal • IO biomarker
    |
    IGH (Immunoglobulin Heavy Locus)
    |
    IGH mutation
    |
    Rituxan (rituximab) • Jaypirca (pirtobrutinib) • bendamustine
    4d
    Mapping B-cell Biology Across the Cardiovascular Territories of Giant Cell Arteritis: Towards a New Therapeutic Approach (RituxiMAP GCA) (clinicaltrials.gov)
    P=N/A, N=30, Not yet recruiting, University of Edinburgh
    New trial
    |
    Rituxan (rituximab)
    4d
    Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma (clinicaltrials.gov)
    P4, N=40, Recruiting, The First Affiliated Hospital of Soochow University
    New P4 trial
    |
    Rituxan (rituximab) • Jakafi (ruxolitinib) • Brukinsa (zanubrutinib)
    4d
    Go-Pro-DLBCL: Golcadomide, Poseltinib, and Rituximab for Relapsed/Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
    P1/2, N=20, Not yet recruiting, Seoul National University Hospital
    New P1/2 trial
    |
    Rituxan (rituximab) • golcadomide (CC-99282) • poseltinib (HM71224)
    4d
    A Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders (clinicaltrials.gov)
    P2, N=162, Active, not recruiting, Bio-Thera Solutions | Recruiting --> Active, not recruiting | Trial primary completion date: May 2025 --> May 2026
    Enrollment closed • Trial primary completion date
    4d
    FIL_V-RBAC: Rituximab, Bendamustine and Cytarabine Followed by Venetoclax in High Risk Elderly Patients With MCL (clinicaltrials.gov)
    P2, N=141, Completed, Fondazione Italiana Linfomi - ETS | Active, not recruiting --> Completed
    Trial completion
    |
    CCND1 (Cyclin D1) • SOX11 (SRY-Box Transcription Factor 11)
    |
    Chr t(11;14)
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • cytarabine • bendamustine